ArticleEClinicalMedicine2023

Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3-18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study).

Zurina Cinza-Estévez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.